OncoMatch/Clinical Trials/NCT06914674
Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas
Is NCT06914674 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tamoxifen 20 mg for pancreatic neoplasms.
Treatment: Tamoxifen 20 mg — Tamoxifen for Solid Pseudopapillary Tumor of the Pancreas
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: ESR1 positive
Required: PR (PGR) positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Kidney function
Severe organ dysfunction (renal) excluded
Liver function
Severe organ dysfunction (hepatic) excluded
Cardiac function
Severe organ dysfunction (cardiac) excluded
Severe organ dysfunction (renal, cardiac, hepatic, or pulmonary)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06914674 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ESR1?
Yes, ESR1 positive is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages